Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Yingjue Li
Observed name:
Y.L. Li
Institution:
Third Affiliated Hospital of Harbin Medical University
Observed institutions:
Harbin Medical University,
Shantou University,
Third Affiliated Hospital of Harbin Medical University,
Second Affiliated Hospital of Shantou University Medical College,
Second Affiliated Hospital of Harbin Medical University
ORCID:
0000-0002-0215-9184
Observed ORCID:
0000-0002-0215-9184
OpenAlex ID:
A5011509895
USP15 Facilitates Colorectal Cancer Immune Evasion through SMYD3/CCL2-Dependent Myeloid-Derived Suppressor Cell Recruitment
2025
·
Shuling Han
, Luying Cui
, et al.
·
Cancer Immunology Research
·
21
Inhibition of KAT6A enhances immunotherapy efficacy in colorectal cancer by activating interferon response
2025
·
Shuling Han
, Zhuo Chen
, et al.
·
Cancer Letters
·
12
Role of Nitric Oxide in Ischemia-Reperfusion Injury and Acute Rejection in Rat Intestinal Transplantation
2008
·
X.L. Li
, X.M. Zou
, et al.
·
Transplantation Proceedings
·
11
Targeting CTGF overcomes resistance to CSF1R inhibitors by preventing CAF activation in colorectal cancer
2025
·
Bojun Wang
, Yingjue Li
, et al.
·
Cell Reports Medicine
·
10
Mevalonate kinase inhibits anti-tumor immunity by impairing the tumor cell-intrinsic interferon response in microsatellite instability colorectal cancer
2024
·
Yuanyu Liao
, Rui Yang
, et al.
·
Oncogene
·
9
Synergistic efficacy of PI3Kδ inhibitor with anti-PD-1 mAbs in immune-humanized PDX model of endocrine resistance hormone receptor-positive advanced breast cancer
2023
·
Yingjue Li
, Yiwen Li
, et al.
·
Heliyon
·
9
PDF
Postoperative pathological complete response in a patient with PD‑L1‑negative stage IIIB lung squamous cell carcinoma following neoadjuvant tislelizumab treatment combined with chemotherapy: A case report and literature review
2023
·
Guanghua Cui
, Di Qu
, et al.
·
Oncology Letters
·
4
PDF
Elevated CHAF1A Suppresses Type I Interferon Production and Causes Immunotherapy Resistance in Esophageal Squamous Cell Carcinoma
2026
·
Yue Ma
, Mengde Shi
, et al.
·
Cancer Immunology Research
·
1
Supplementary Fig. S2 from Elevated CHAF1A Suppresses Type I Interferon Production and Causes Immunotherapy Resistance in Esophageal Squamous Cell Carcinoma
2026
·
Yue Ma
, Mengde Shi
, et al.
Data from Elevated CHAF1A Suppresses Type I Interferon Production and Causes Immunotherapy Resistance in Esophageal Squamous Cell Carcinoma
2026
·
Yue Ma
, Mengde Shi
, et al.
Supplementary Fig. S1 from Elevated CHAF1A Suppresses Type I Interferon Production and Causes Immunotherapy Resistance in Esophageal Squamous Cell Carcinoma
2026
·
Yue Ma
, Mengde Shi
, et al.
Supplementary Fig. S4 from Elevated CHAF1A Suppresses Type I Interferon Production and Causes Immunotherapy Resistance in Esophageal Squamous Cell Carcinoma
2026
·
Yue Ma
, Mengde Shi
, et al.
Supplementary Tables from Elevated CHAF1A Suppresses Type I Interferon Production and Causes Immunotherapy Resistance in Esophageal Squamous Cell Carcinoma
2026
·
Yue Ma
, Mengde Shi
, et al.
Supplementary Fig. S6 from Elevated CHAF1A Suppresses Type I Interferon Production and Causes Immunotherapy Resistance in Esophageal Squamous Cell Carcinoma
2026
·
Yue Ma
, Mengde Shi
, et al.
Supplementary Fig. S3 from Elevated CHAF1A Suppresses Type I Interferon Production and Causes Immunotherapy Resistance in Esophageal Squamous Cell Carcinoma
2026
·
Yue Ma
, Mengde Shi
, et al.
Supplementary Fig. S5 from Elevated CHAF1A Suppresses Type I Interferon Production and Causes Immunotherapy Resistance in Esophageal Squamous Cell Carcinoma
2026
·
Yue Ma
, Mengde Shi
, et al.
Supplementary Fig. S7 from Elevated CHAF1A Suppresses Type I Interferon Production and Causes Immunotherapy Resistance in Esophageal Squamous Cell Carcinoma
2026
·
Yue Ma
, Mengde Shi
, et al.
Supplementary Figure 10 from USP15 Facilitates Colorectal Cancer Immune Evasion through SMYD3/CCL2-Dependent Myeloid-Derived Suppressor Cell Recruitment
2025
·
Shuling Han
, Luying Cui
, et al.
Supplementary Figure 2 from USP15 Facilitates Colorectal Cancer Immune Evasion through SMYD3/CCL2-Dependent Myeloid-Derived Suppressor Cell Recruitment
2025
·
Shuling Han
, Luying Cui
, et al.
Supplementary Figure 5 from USP15 Facilitates Colorectal Cancer Immune Evasion through SMYD3/CCL2-Dependent Myeloid-Derived Suppressor Cell Recruitment
2025
·
Shuling Han
, Luying Cui
, et al.
Supplementary Figure 3 from USP15 Facilitates Colorectal Cancer Immune Evasion through SMYD3/CCL2-Dependent Myeloid-Derived Suppressor Cell Recruitment
2025
·
Shuling Han
, Luying Cui
, et al.
Supplementary Figure 11 from USP15 Facilitates Colorectal Cancer Immune Evasion through SMYD3/CCL2-Dependent Myeloid-Derived Suppressor Cell Recruitment
2025
·
Shuling Han
, Luying Cui
, et al.
Supplementary Figure 1 from USP15 Facilitates Colorectal Cancer Immune Evasion through SMYD3/CCL2-Dependent Myeloid-Derived Suppressor Cell Recruitment
2025
·
Shuling Han
, Luying Cui
, et al.
Data from USP15 Facilitates Colorectal Cancer Immune Evasion through SMYD3/CCL2-Dependent Myeloid-Derived Suppressor Cell Recruitment
2025
·
Shuling Han
, Luying Cui
, et al.
Supplementary Table 3 from USP15 Facilitates Colorectal Cancer Immune Evasion through SMYD3/CCL2-Dependent Myeloid-Derived Suppressor Cell Recruitment
2025
·
Shuling Han
, Luying Cui
, et al.
Show more works
View as search
Works count:
32
Citation count:
77
H-index:
6
I10-index:
4
Year
Topic
Type